 Biopharmaceutical outfit Sorrento Therapeutics US:SRNE rallied 6.2 on Tuesday and extended gains by a further 2.1 in post market trading after the company released positive trial results cnx.cmd.pushfunction var videoId decodeURIComponent; cnx playerId: 0a52d238-33b5-4c04-ba5e-323e192cfbe8, mediaId: videoId.renderb8b49474e42e4a61905a1353db504ac9; ; from Abivertinib that was used for the treatment of Advanced Non-Small Cell Lung Cancer NSCLC. 